VRTXVERTEX PHARMACEUTICALS INC / MAvs its industry peers
A metric-by-metric comparison of VERTEX PHARMACEUTICALS INC / MA against its industry peers — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX본 종목 | $124.5B#3 | 29.1x#4 | 6.4x#1 | 10.4x#3 | 8.9%#2 | 838.1%#2 | 34.8%#1 | 20.4%#3 | 25.4%#1 | — | 4.6%#4 | — |
| REGN | — | 17.0x#1 | — | — | 1.0%#4 | 2.1%#4 | 24.9%#3 | 14.3%#4 | 9.6%#4 | — | 24.6%#2 | — |
| AMGN | $212.1B#1 | 27.4x#3 | 23.1x#3 | 5.8x#2 | 10.0%#1 | 88.5%#3 | 24.7%#4 | 83.9%#1 | 15.3%#3 | — | 32.7%#1 | 2.4%#1 |
| GILD | $166.8B#2 | 18.3x#2 | 7.1x#2 | 5.7x#1 | 2.4%#3 | 1672.9%#1 | 34.0%#2 | 36.2%#2 | 21.6%#2 | — | 20.4%#3 | 2.4%#2 |
Peer set: Tickwind's hand-curated industry grouping. Values from SEC filings + delayed prices; ranks are sorted positions within this group only — descriptive, not a rating or advice. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-07-29.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice